Adam Schiffenbauer

872 total citations
25 papers, 329 citations indexed

About

Adam Schiffenbauer is a scholar working on Epidemiology, Rheumatology and Immunology. According to data from OpenAlex, Adam Schiffenbauer has authored 25 papers receiving a total of 329 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Epidemiology, 13 papers in Rheumatology and 7 papers in Immunology. Recurrent topics in Adam Schiffenbauer's work include Inflammatory Myopathies and Dermatomyositis (18 papers), Eosinophilic Disorders and Syndromes (6 papers) and Dermatological and Skeletal Disorders (4 papers). Adam Schiffenbauer is often cited by papers focused on Inflammatory Myopathies and Dermatomyositis (18 papers), Eosinophilic Disorders and Syndromes (6 papers) and Dermatological and Skeletal Disorders (4 papers). Adam Schiffenbauer collaborates with scholars based in United States, Canada and Australia. Adam Schiffenbauer's co-authors include Frederick W. Miller, Lisa G. Rider, Brian D. Poole, Jing Zhou, Stanley J. Naides, Ira N. Targoff, Sara Faghihi‐Kashani, Terrance P. OʼHanlon, Paul H. Plötz and Karen G. Malley and has published in prestigious journals such as Journal of Virology, Scientific Reports and Journal of Allergy and Clinical Immunology.

In The Last Decade

Adam Schiffenbauer

22 papers receiving 322 citations

Peers

Countries citing papers authored by Adam Schiffenbauer

Since Specialization

Citations

This map shows the geographic impact of Adam Schiffenbauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Schiffenbauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Schiffenbauer more than expected).

Fields of papers citing papers by Adam Schiffenbauer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam Schiffenbauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Schiffenbauer. The network helps show where Adam Schiffenbauer may publish in the future.

Co-authorship network of co-authors of Adam Schiffenbauer

This figure shows the co-authorship network connecting the top 25 collaborators of Adam Schiffenbauer. A scholar is included among the top collaborators of Adam Schiffenbauer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam Schiffenbauer. Adam Schiffenbauer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Myositis-specific autoantibodies recognising Mi2 also target the AIRE protein at a shared PHD zinc finger 2025 ·Annals of the Rheumatic Diseases ·(unknown), (unknown), Katherine Pak, Iago Pinal‐Fernandez, (unknown), María Casal-Domínguez, (unknown), (unknown), Peter D. Burbelo, Mariana J. Kaplan, Blake M. Warner, Adam Schiffenbauer, Albert Selva-O’Callaghan, José C. Milisenda, Lisa G. Rider, H. Benjamin Larman, Andrew L. Mammen	1
2	Stressful life events are associated with the diagnosis of systemic autoimmune rheumatic diseases among adults 2025 ·Clinical and Experimental Rheumatology ·Iazsmin Bauer Ventura, Michael E. Goldberg, Adam Schiffenbauer, Min Shi, (unknown), Sharon H. Jackson, (unknown), Nastaran Bayat, (unknown), Christine G. Parks, Clarice R. Weinberg, Angelo Picardi, Frederick W. Miller, Lisa G. Rider	2
3	Imaging assessment of calcinosis in juvenile dermatomyositis: a narrative review 2025 ·Pediatric Rheumatology ·(unknown), (unknown), (unknown), Kelly Rouster‐Stevens, Amanda Robinson, (unknown), Delaney D Ding, A Child, (unknown), (unknown), Charalampia Papadopoulou, Lesley Ann Saketkoo, Adam Schiffenbauer, Heinrike Schmeling, Antonia Valenzuela, Susan Shenoi, Dawn M. Wahezi, (unknown)	0
4	Factors associated with interstitial lung disease among patients with idiopathic inflammatory myopathies 2025 ·Lara D. Veeken ·Jesse Wilkerson, Frederick W. Miller, (unknown), (unknown), Shepherd H. Schurman, Stavros Garantziotis, (unknown), Adam Schiffenbauer, Lisa G. Rider	1
5	Neutrophil and mononuclear leukocyte pathways and upstream regulators revealed by serum proteomics of adult and juvenile dermatomyositis 2024 ·Arthritis Research & Therapy ·(unknown), James M. Ward, Kakali Sarkar, Adam Schiffenbauer, (unknown), Michael A. Smith, Saifur Rahman, Kamelia Zerrouki, Frederick W. Miller, Jian‐Liang Li, Kerry A. Casey, Lisa G. Rider	0
6	Familial clustering of dysbiotic oral and fecal microbiomes in juvenile dermatomyositis 2024 ·Scientific Reports ·(unknown), Albert Chow, (unknown), Peggy Lee, (unknown), Laurie Brenchley, Pamela J. Gardner, (unknown), (unknown), Adam Schiffenbauer, (unknown), Nastaran Bayat, Jeffrey S. McLean, Lisa G. Rider, Susan Shenoi, Anne M. Stevens, Neelendu Dey	0
7	Occupational and Hobby Exposures Associated With Myositis Phenotypes in a National Myositis Patient Registry 2024 ·Arthritis Care & Research ·Christine G. Parks, Jesse Wilkerson, (unknown), (unknown), (unknown), Nastaran Bayat, Adam Schiffenbauer, Hermine I. Brunner, (unknown), Dale P. Sandler, Frederick W. Miller, Lisa G. Rider	1
8	Mepolizumab incompletely suppresses clinical flares in a pilot study of episodic angioedema with eosinophilia 2023 ·Journal of Allergy and Clinical Immunology ·Paneez Khoury, Michelle Makiya, (unknown), (unknown), D. Nicolás Espinoza, Adam Schiffenbauer, (unknown), Charles E. Anderson, Gregory Constantine, Irina Marić, Xiaoping Sun, Stefania Pittaluga, Thomas D. Brown, JeanAnne Ware, Lauren Wetzler, Michael P. Fay, Amy D. Klion	3
9	Shared and Distinctive Transcriptomic and Proteomic Pathways in Adult and Juvenile Dermatomyositis 2023 ·Arthritis & Rheumatology ·James M. Ward, (unknown), Terrance P. OʼHanlon, Michael A. Smith, Melissa de los Reyes, Adam Schiffenbauer, Saifur Rahman, Kamelia Zerrouki, Frederick W. Miller, Miguel A. F. Sanjuán, Jian‐Liang Li, Kerry A. Casey, Lisa G. Rider	12
10	Efficacy of topical ruxolitinib for cutaneous dermatomyositis 2023 ·JAAD Case Reports ·(unknown), Hanna Kim, Shajia Lu, Wanxia Li Tsai, (unknown), Alison Ehrlich, George M. Martin, Adam Schiffenbauer, Susan Shenoi	2
11	Development of a computed tomography calcium scoring technique for assessing calcinosis distribution, pattern and burden in dermatomyositis 2023 ·Lara D. Veeken ·(unknown), (unknown), Lisa G. Rider, Frederick W. Miller, Marcus Y. Chen, Adam Schiffenbauer	3
12	Environmental factors associated with juvenile idiopathic inflammatory myopathy clinical and serologic phenotypes 2022 ·Pediatric Rheumatology ·(unknown), Adam Schiffenbauer, (unknown), (unknown), Nastaran Bayat, (unknown), Ira N. Targoff, Frederick W. Miller, Lisa G. Rider	3
13	Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus 2020 ·Scientific Reports ·Michael A. Smith, Chia-Chien Chiang, Kamelia Zerrouki, Saifur Rahman, Wendy I. White, Katie Streicher, William A. Rees, Adam Schiffenbauer, Lisa G. Rider, Frederick W. Miller, Zerai Manna, Sarfaraz Hasni, Mariana J. Kaplan, Richard M. Siegel, Dominic Sinibaldi, Miguel A. F. Sanjuán, Kerry A. Casey	18
14	Rheumatology capacity building: implementing a rheumatology curriculum for Liberian health-care providers in 2016 2020 ·Clinical Rheumatology ·Laura B. Lewandowski, Adam Schiffenbauer, JoAnn M. Mican, Moses J Soka, (unknown), Paul H. Plötz, James D. Katz	7
15	Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis 2020 ·Autoimmunity Reviews ·Melody P. Chung, Carrie Richardson, David Kirakossian, (unknown), Lesley Ann Saketkoo, Lisa G. Rider, Adam Schiffenbauer, Carlos Alberto von Mühlen, Leland W.K. Chung	37
16	Long-term outcomes in Juvenile Myositis patients 2019 ·Seminars in Arthritis and Rheumatism ·(unknown), (unknown), (unknown), Anna Yakovleva, (unknown), Gulnara Mamyrova, Ira N. Targoff, Adam Schiffenbauer, Frederick W. Miller, Samuel J. Simmens, Rodolfo Curiel, (unknown), Lisa G. Rider	21
17	The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis 2018 ·Seminars in Arthritis and Rheumatism ·Adam Schiffenbauer, Sara Faghihi‐Kashani, (unknown), Willy A. Flegel, Sharon Adams, Ira N. Targoff, Chester V. Oddis, Steven R. Ytterberg, Rohit Aggarwal, Lisa Christopher‐Stine, Ejaz A. Shamim, Paul F. Dellaripa, Sonye K. Danoff, Andrew L. Mammen, Frederick W. Miller	32
18	A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis 2017 ·Seminars in Arthritis and Rheumatism ·Adam Schiffenbauer, (unknown), Christine Castro, (unknown), Galen O. Joe, Joseph A. Shrader, (unknown), Sara Faghihi‐Kashani, Michael O. Harris‐Love, Paul H. Plötz, Frederick W. Miller, Mark F. Gourley	46
19	Imaging 2014 ·Current Opinion in Rheumatology ·Adam Schiffenbauer	7
20	Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies 2008 ·Arthritis & Rheumatism ·Terrance P. OʼHanlon, Lisa G. Rider, Adam Schiffenbauer, Ira N. Targoff, Karen G. Malley, Janardan P. Pandey, Frederick W. Miller	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact